Gemcitabine/carboplatin in advanced non-small cell lung cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F02%3A00003693" target="_blank" >RIV/00216208:11120/02:00003693 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S0169-5002(02)00355-0" target="_blank" >http://dx.doi.org/10.1016/S0169-5002(02)00355-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S0169-5002(02)00355-0" target="_blank" >10.1016/S0169-5002(02)00355-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gemcitabine/carboplatin in advanced non-small cell lung cancer

Popis výsledku v původním jazyce

Gemcitabine/cisplatin is among the most widely used regimens in Europe for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologic toxicity and difficulty of use in outpatients. Carboplatin constitutes a reasonable alternative to cisplatin in this combination, since it shows synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematologic toxicity profile. Studies of gemcitabine/cisplatin on a 28-day schedule (gemcitabine on days 1, 8, 15 and carboplatin on day 1) generally indicate excessive thrombocytopenia. Use of a 21-day schedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity and comparable efficacy. Results of one randomized phase II study suggest reduced toxicity and reduced objective response rate with gemcitabine/carboplatin versus gemcitabine/cisplatin. We are currently conducting a phase III comparison of

Název v anglickém jazyce

Gemcitabine/carboplatin in advanced non-small cell lung cancer

Popis výsledku anglicky

Gemcitabine/cisplatin is among the most widely used regimens in Europe for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologic toxicity and difficulty of use in outpatients. Carboplatin constitutes a reasonable alternative to cisplatin in this combination, since it shows synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematologic toxicity profile. Studies of gemcitabine/cisplatin on a 28-day schedule (gemcitabine on days 1, 8, 15 and carboplatin on day 1) generally indicate excessive thrombocytopenia. Use of a 21-day schedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity and comparable efficacy. Results of one randomized phase II study suggest reduced toxicity and reduced objective response rate with gemcitabine/carboplatin versus gemcitabine/cisplatin. We are currently conducting a phase III comparison of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2002

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lung Cancer

ISSN

0169-5002

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

Suppl. 2

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

4

Strana od-do

"S33"-"S36"

Kód UT WoS článku

000179743100008

EID výsledku v databázi Scopus

—